Evidence map›Paper›PMID 38710856›Full record

ArticlePsychopharmacology2024

Pharmacologic profile of ITI-333: a novel molecule for treatment of substance use disorders.

Gretchen L Snyder, Peng Li, Terry Martin, Lei Zhang, Wei Yao, Hailin Zheng, David R Maguire, Lisa R Gerak, Kimberly E Vanover, Charles P France and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Gretchen L SnyderIntra-Cellular Therapies Inc., 430 East 29th Street, Suite 900, New York, NY, 10016, USA. gsnyder@itci-inc.com.ORCID http://orcid.org/0000-0003-4749-686X
Peng LiIntra-Cellular Therapies Inc., 430 East 29th Street, Suite 900, New York, NY, 10016, USA.
Terry MartinIntra-Cellular Therapies Inc., 430 East 29th Street, Suite 900, New York, NY, 10016, USA.
Lei ZhangIntra-Cellular Therapies Inc., 430 East 29th Street, Suite 900, New York, NY, 10016, USA.
Wei YaoIntra-Cellular Therapies Inc., 430 East 29th Street, Suite 900, New York, NY, 10016, USA.
Hailin ZhengIntra-Cellular Therapies Inc., 430 East 29th Street, Suite 900, New York, NY, 10016, USA.
David R MaguireUniversity of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive (Mail Code 7764), San Antonio, TX, 78229-3900, USA.
Lisa R GerakUniversity of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive (Mail Code 7764), San Antonio, TX, 78229-3900, USA.
Kimberly E VanoverEngrail Therapeutics, San Diego, CA, 92130, USA.
Charles P FranceUniversity of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive (Mail Code 7764), San Antonio, TX, 78229-3900, USA.
Robert DavisIntra-Cellular Therapies Inc., 430 East 29th Street, Suite 900, New York, NY, 10016, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleMedications are urgently needed to treat symptoms of drug withdrawal and mitigate dysphoria and psychiatric comorbidities that drive opioid abuse and relapse. ITI-333 is a novel molecule in development for treatment of substance use disorders, psychiatric comorbidities, and pain.

objectiveCharacterize the preclinical profile of ITI-333 using pharmacological, behavioral, and physiological assays.

methodsCell-based assays were used to measure receptor binding and intrinsic efficacy of ITI-333; animal models were employed to assess effects on opioid reinstatement, precipitated oxycodone withdrawal, and drug abuse liability.

resultsIn vitro, ITI-333 is a potent 5-HT

conclusionsITI-333 acts as a potent 5-HT

Indexed as

Substance Withdrawal SyndromeAnalgesics, OpioidAnimalsCHO CellsCricetulusDose-Response Relationship, DrugHumansMaleMiceOpioid-Related DisordersOxycodoneRatsRats, Sprague-DawleyReceptors, Opioid, muSelf AdministrationSerotonin 5-HT2 Receptor AntagonistsAnalgesics, OpioidOxycodoneReceptors, Opioid, muSerotonin 5-HT2 Receptor Antagonists5-HT2A receptorBeta arrestinCue-induced heroin reinstatementMorphineMu opioid receptorOpioid use disorderPartial agonist

Identifiers

PMID38710856
PMCPMC11199232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.